Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852153 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL2852156 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL570033 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL21483554 | 0.86 | MEN1 (0.46) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3025341 | 0.84 | MAOA (0.44) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31236580 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31236478 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31236543 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31236527 | 0.83 | MEN1 (0.36) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL1222350 | 0.83 | TDP1 (0.49) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106893342-A | A kind of dimethylbenzene green grass or young crops FF derivative dyes and its synthetic method | 宁波普芯生物科技有限公司 | 2017-06-27 | — | — | CN | claimed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025068132-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025012195-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| WO-2006009832-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005066172-A1 | PIPERAZINE, [1,4]DIAZEPANE, [1,4]DIAZOCANE, AND [1,5]DIAZOCANE FUSED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2003093346-A1 | MULTIFUNCTIONAL POLYETHYLENE GLYCOL DERIVATIVES: PREPARATION AND USE | UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) | 2003-11-13 | — | — | WO | disclosed |
| US-20020049191-A1 | Cephalosporin derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-5734047-A | GRAM-POSITIVE ANTIBACTERIAL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1997022611-A1 | CEPHALOSPORIN DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0496561-B1 | [[(2-Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives | AMERICAN HOME PROD (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5240946-A | Anticonvulsants, nervous system disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-5168103-A | Neuroprotectants, anticonvulsants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-12-01 | — | — | US | disclosed |
| EP-0496561-A2 | [[(2-Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | MEN1 1496/4885GAA 1245/4885KMT2A 2443/4885 |
| US-20020049191-A1 | Cephalosporin derivatives | MRPL21, CIAPIN1, LTN1 | MEN1 1330/4885GAA 2139/4885KMT2A 4106/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | MEN1 1812/4885GAA 3145/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.